A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00035061 |
Recruitment Status :
Completed
First Posted : May 3, 2002
Last Update Posted : July 19, 2006
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Urologic Neoplasms Metastases, Neoplasm | Drug: pemetrexed | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Primary Purpose: | Treatment |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- You must have been diagnosed with bladder cancer that has recurred or moved to a new part of the body.
- You must have at least one tumor that can be physically measured or scanned by x-ray.
- You may not have had previous chemotherapy (drug) treatment OR you have had surgery followed by one chemotherapy treatment at least 4 months ago.
Exclusion Criteria:
- You may not have used an experimental medicine or device within the past month.
- Cancer that has spread to your brain.
- If you are unwilling or unable to take folic acid or vitamin B12 supplements.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00035061
United States, California | |
Los Angeles, California, United States | |
Palo Alto, California, United States | |
United States, Florida | |
Boca Raton, Florida, United States | |
Tampa, Florida, United States | |
United States, Illinois | |
Decatur, Illinois, United States | |
United States, Indiana | |
Indianapolis, Indiana, United States | |
Lafayette, Indiana, United States | |
Muncie, Indiana, United States | |
South Bend, Indiana, United States | |
United States, Kansas | |
Lenexa, Kansas, United States | |
United States, Kentucky | |
Saint Mathews, Kentucky, United States | |
United States, Massachusetts | |
Boston, Massachusetts, United States | |
United States, Nebraska | |
Omaha, Nebraska, United States | |
United States, Ohio | |
Cleveland, Ohio, United States | |
United States, Pennsylvania | |
Philadelphia, Pennsylvania, United States | |
Pittsburgh, Pennsylvania, United States | |
United States, Tennessee | |
Nashville, Tennessee, United States | |
United States, Texas | |
Fort Worth, Texas, United States | |
Houston, Texas, United States | |
United States, Washington | |
Seattle, Washington, United States |
ClinicalTrials.gov Identifier: | NCT00035061 |
Obsolete Identifiers: | NCT00039260 |
Other Study ID Numbers: |
4698 H3E-MC-JMEU |
First Posted: | May 3, 2002 Key Record Dates |
Last Update Posted: | July 19, 2006 |
Last Verified: | July 2006 |
Bladder Cancer Metastatic Recurrent Transitional cell carcinoma of the urothelium |
Neoplasms Neoplasm Metastasis Carcinoma, Transitional Cell Urologic Neoplasms Neoplastic Processes Pathologic Processes Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type |
Urogenital Neoplasms Neoplasms by Site Pemetrexed Antineoplastic Agents Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Folic Acid Antagonists Nucleic Acid Synthesis Inhibitors |